OverviewSuggest Edit

Nuformix (formerly known as Levrett) is a company that develops pharmaceutical products. The Company uses cocrystal technology. Its products include NXP001 for oncology supportive care, NXP002 for use in the treatment of fibrosis, and NXP003.

TypePublic
Founded2008
HQCambridge, GB
Websitenuformix.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2017)1
Revenue (FY, 2019)£610 K(+3967%)
Share Price (Jun 2020)£3.8 (+3%)
Cybersecurity ratingAMore

Key People/Management at Nuformix

Daniel Gooding

Daniel Gooding

Chief Executive Officer
Joanne Holland

Joanne Holland

Chief Scientific Officer
Karl Keegan

Karl Keegan

Non-Executive Director
David Tapolczay

David Tapolczay

Chairman
Christopher Blackwell

Christopher Blackwell

Non-Executive Director
Show more

Nuformix Office Locations

Nuformix has offices in Cambridge and London
Cambridge, GB (HQ)
153 Cambridge Science Park Milton Road
London, GB
6th floor, 60 Gracechurch St
Show all (2)

Nuformix Financials and Metrics

Nuformix Revenue

Embed Graph
View revenue for all periods
Nuformix's revenue was reported to be £610 k in FY, 2019
GBP

Revenue (FY, 2019)

610.0k

Gross profit (FY, 2019)

72.5k

Gross profit margin (FY, 2019), %

11.9%

Net income (FY, 2019)

(1.7m)

EBIT (FY, 2019)

(1.8m)

Market capitalization (26-Jun-2020)

18.9m

Closing stock price (26-Jun-2020)

3.8

Cash (31-Mar-2019)

4.3k

EV

18.9m
Nuformix's current market capitalization is £18.9 m.
GBPFY, 2018FY, 2019

Revenue

15.0k610.0k

Cost of goods sold

203.9k537.5k

Gross profit

(188.9k)72.5k

Gross profit Margin, %

(1259%)12%
GBPFY, 2017FY, 2018FY, 2019

Cash

4.4k338.2k4.3k

Accounts Receivable

9.2k887.0

Current Assets

88.6k713.7k347.0k
GBPFY, 2017FY, 2018FY, 2019

Cash From Operating Activities

117.5k(1.5m)(299.3k)

Cash From Investing Activities

(93.3k)(100.6k)(27.3k)

Cash From Financing Activities

(21.4k)2.0m(7.3k)

Net Change in Cash

2.9k333.7k(333.9k)
GBPFY, 2017

Financial Leverage

-1.5 x
Show all financial metrics

Nuformix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Nuformix Online and Social Media Presence

Embed Graph

Nuformix Blogs

Additional New NXP002 Patent Filing

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs is pleased to announce a new patent filing in connection with its NXP002 fibrosis programme. The post Additional New NXP002 Patent Filing appeared first on…

NXP001 Pre-Clinical Milestone Achieved

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs is pleased to announce that in accordance with its agreement with Newsummit Biopharma (“NSB”) the pre-clinical milestone for NXP001 has been achieved, trig…
Show more

Nuformix Frequently Asked Questions

  • When was Nuformix founded?

    Nuformix was founded in 2008.

  • Who are Nuformix key executives?

    Nuformix's key executives are Daniel Gooding, Joanne Holland and Karl Keegan.

  • How many employees does Nuformix have?

    Nuformix has 1 employees.

  • What is Nuformix revenue?

    Latest Nuformix annual revenue is £610 k.

  • What is Nuformix revenue per employee?

    Latest Nuformix revenue per employee is £610 k.

  • Who are Nuformix competitors?

    Competitors of Nuformix include SmartZyme, Servier and Patheon.

  • Where is Nuformix headquarters?

    Nuformix headquarters is located at 153 Cambridge Science Park Milton Road, Cambridge.

  • Where are Nuformix offices?

    Nuformix has offices in Cambridge and London.

  • How many offices does Nuformix have?

    Nuformix has 2 offices.